Minichromosome maintenance protein 6 (MCM6) is one of six proteins of the MCM family which are involved in the initiation of DNA replication and thus represent a marker of proliferating cells. Since the level of cell proliferation is the most valuable predictor of survival in mantle cell lymphoma (MCL), we investigated lymph node biopsy specimens from 70 patients immunohistochemically with a monoclonal antibody against MCM6. The percentage of MCM6-expressing lymphoma cells ranged from 12.0 to 95.6%, with a mean of 61.0%, and was significantly higher than the percentage of Ki-67-positive cells (P < 0.0001). Surprisingly, the ratio of MCM6-positive cells to Ki-67-positive cells was higher than in normal stimulated peripheral blood mononuclear cells, indicating a cell early G1-phase arrest in MCL. A high MCM6 expression level of more than 75% positive cells was associated with a significantly shorter overall survival time (16 months) compared to MCL with a low MCM6 expression level of less than 25% (no median reached, P < 0.0001). Multivariate analysis revealed MCM6 to be an independent predictor of survival that is superior to the international prognostic factor and the Ki-67 index. Therefore, aside from gene expression profiling, immunohistochemical detection of MCM6 seems to be the most promising marker for predicting the outcome in MCL.

Mantle cell lymphoma (MCL) is a B-cell neoplasm characterised by a typical immunophenotype and the chromosomal translocation t(11;14) (Tsujimoto et al., 1984; Campo et al., 1999; Bertoni et al., 2004). The clinical course of MCL, although heterogeneous, is usually poor, with a survival time of 3–4 years. For several years a high proliferation rate, as measured by counting the number of mitotic figures or of Ki-67-expressing cells, has been recognised as a marker of poor prognosis (Lardelli et al., 1990; Velders et al., 1996; Raty et al., 2002). However, due to the lack of data from prospective trials and the limited predictive power of the markers available so far, cell proliferation has rarely been used for clinical decision-making in MCL. Studies of gene expression profiling demonstrated that a set of genes, designated as the proliferation signature, can predict the clinical outcome of patients with MCL with so far unrivalled precision (Martinez et al., 2003; Rosenwald et al., 2003; Ek et al., 2004). These studies have stimulated the search for new immunohistochemical markers of proliferation that might take the place of gene expression profiling as a predictor of outcome in MCL.

Minichromosome maintenance (MCM) proteins play an important role in the replication of eukaryotic DNA by binding to chromatin before the initiation of DNA replication (Fujita et al., 1997; Ogawa et al., 1999). Minichromosome maintenance protein 6 (MCM6) is one of six members (MCM2–7) of the MCM family (Lindner et al., 2002) and consists of 821 amino acids with a molecular mass of 105 kDa (Heidebrecht et al., 2001). We have recently developed a specific monoclonal antibody against MCM6 (Ki-MCM6) (Heidebrecht et al., 2001) that enables the accurate detection of MCM6 in paraffin-embedded tissue (Heidebrecht et al., 2001; Helfenstein et al., 2004). Using Ki-MCM6, Heidebrecht et al. (2001) showed that MCM6 is detectable in nucleosols or bound to nuclear chromatin during the entire cell cycle phases (positive in G1, S, G2 and M phases, but is absent in G0 phase (Labib et al., 2001). Despite this similar expression pattern of MCM6 and Ki-67 during the cell cycle phases (positive in G1, S, G2 and M phases), detailed cell cycle analysis reveals differences between both markers. During the early G1 phase Ki-67 is undetectable, whereas MCM6 is expressed in the entire G1 phase. Therefore, a small subset of about 20% of proliferating cells in early G1 phase could be detected by MCM6 and not by Ki-67 in stimulated peripheral blood mononuclear cells (Heidebrecht et al., 2001).
The clinical relevance of MCM proteins as proliferation markers has been investigated immunohistochemically in several different malignant tumours (Freeman et al., 1999), for example, non-small-cell lung cancer (Ramnath et al., 2001), prostate cancer (Meng et al., 2001; Padmanabhan et al., 2004), oral squamous cell carcinoma (Kodani et al., 2003), chondrosarcoma (Helfenstein et al., 2004), oligodendrogial tumours (Wharton et al., 2001, 2004), endometrial carcinoma (Li et al., 2005) and thyroid carcinoma (Guida et al., 2005). Most of these studies focused on the detection of MCM2 (Freeman et al., 1999; Chatrath et al., 2003; Davidson et al., 2003; Kodani et al., 2003; Scott et al., 2004). So far only few investigations studied MCM6 expression (Labib et al., 2001; Helfenstein et al., 2004).

The MCM2 expression was also analysed in 36 patients with malignant B-cell lymphomas, including 11 cases with MCL (Obermann et al., 2005). The authors included also Ki-67 and geminin (Lygerou and Nurse, 2000; Wohlschlegel et al., 2000; Madine and Laskey, 2001) in their study and could demonstrate that low-grade lymphomas reside in an ‘in-cycle’ G1 state and not in G0. In this very important study of Obermann et al. (2005), the authors did not analyse the MCM2 expression in relation to clinical data.

The aim of this study was to investigate MCM as a new proliferation marker in a large group of patients with MCL and to correlate the results with established prognostic factors for this disease. Since we have developed an antibody that accurately identifies MCM6 in paraffin-embedded tissues, an expression pattern that was tested in normal peripheral blood mononuclear cells (Heidebrecht et al., 2001), we chose this antibody to determine MCM protein expression in this lymphoma.

**Table 1** Univariate analysis of prognostic factors in relation to MCM6 expression

|                  | N  | Median (months) | P-value | MCM6 expression (%) | Mean ± s.d. | Median  | Range       | P-value |
|------------------|----|----------------|---------|---------------------|-------------|---------|-------------|---------|
| **Age**          |    |                |         |                     |             |         |             |         |
| <60              | 28 | 37             | 0.002   |                     | 55.5 ± 23.5 | 55.0    | 14.8 – 90.6 | 0.098   |
| >60              | 42 | 23             |         |                     | 64.6 ± 19.8 | 66.2    | 12.0 – 95.6 |         |
| **Sex**          |    |                |         |                     |             |         |             |         |
| Male             | 57 | 29             | 0.688   |                     | 61.0 ± 21.3 | 65.4    | 12.0 – 95.6 | 0.605   |
| Female           | 13 | 28.8           |         |                     | 58.1 ± 24.2 | 60.4    | 14.8 – 90.4 |         |
| **B-symptoms**   |    |                |         |                     |             |         |             |         |
| Yes              | 25 | 17.0           | 0.002   |                     | 67.8 ± 18.5 | 70.0    | 25.8 – 91.8 | 0.027   |
| No               | 43 | 35.7           |         |                     | 55.9 ± 22.3 | 57.0    | 12.0 – 95.6 |         |
| **BM infiltration** |   |                |         |                     |             |         |             |         |
| Yes              | 42 | 28.0           | 0.138   |                     | 62.1 ± 19.7 | 65.6    | 12.0 – 90.6 | 0.488   |
| No               | 27 | 33.0           |         |                     | 58.2 ± 24.6 | 57.0    | 14.8 – 95.6 |         |
| **Stage**        |    |                |         |                     |             |         |             |         |
| I + 2            | 5  | 42.3           | 0.249   |                     | 57.3 ± 19.6 | 56.3    | 33.6 – 87.9 | 0.638   |
| 3 + 4            | 59 | 28.0           |         |                     | 62.1 ± 21.9 | 66.0    | 12.0 – 95.6 |         |
| **Status (WHO)** |    |                |         |                     |             |         |             |         |
| 0 – 1            | 53 | 31.0           | 0.013   |                     | 58.3 ± 21.7 | 60.4    | 12.0 – 95.6 | 0.014   |
| ≥ 2              | 15 | 19.9           |         |                     | 73.5 ± 16.6 | 74.0    | 35.6 – 90.6 |         |
| **Extranodal**   |    |                |         |                     |             |         |             |         |
| Yes              | 58 | 29.0           | 0.157   |                     | 60.6 ± 21.5 | 65.7    | 12.0 – 92.8 | 0.773   |
| No               | 12 | 28.8           |         |                     | 62.6 ± 23.7 | 62.3    | 14.8 – 95.6 |         |
| **LDH**          |    |                |         |                     |             |         |             |         |
| <240             | 51 | 29.0           | 0.043   |                     | 60.6 ± 21.5 | 63.2    | 12.0 – 95.6 | 0.055   |
| >240             | 13 | 17.9           |         |                     | 73.1 ± 15.4 | 73.2    | 37.2 – 91.8 |         |
| **IPI**          |    |                |         |                     |             |         |             |         |
| 0 – 1            | 17 | 40.0           | 0.007   |                     | 53.0 ± 22.9 | 56.3    | 14.8 – 87.9 | 0.082   |
| ≥ 2              | 53 | 25.4           |         |                     | 63.5 ± 20.9 | 66.4    | 12.0 – 95.6 |         |

BM = bone marrow; stage = Ann Arbor stage; status = performance status; extranodal = extranodal involvement; LDH = lactate dehydrogenase; IPI = International Prognostic Index; full data are not available for all patients.
cyclin-D1 (dilution 1:20) (Novocastra), MCM6 (dilution 1:1, cell culture supernatant) (Ki-MCM6, Department of Hematopathology, University of Kiel, Germany) and anti-Ki-67 (dilution 1:1, cell culture supernatant) (Ki-S5, Department of Hematopathology, University of Kiel, Germany). The stainings were evaluated by investigators blinded to the clinical information. In each stained section 500 neoplastic cells were counted. The MCM6 index was calculated as the percentage of positive nuclei. Only nuclear staining was counted as MCM6 positive.

Tonsil tissue was used as positive controls; negative control samples were incubated with serum instead of the primary antibody.

Statistical methods

For the statistical tests SPSS (SPSS Inc., version 11, Chicago, IL, USA) was used. Various parameters were analysed statistically by two-sided t-test and the correlation coefficient, as indicated. Overall survival analysis (univariate) was analysed by the Kaplan–Meier method. Differences in significance ($P \leq 0.05$) were assessed by means of the log-rank test. All clinical parameters were also compared by means of a multivariate Cox regression analysis using a stepwise (forward and backward) conditional approach.

RESULTS

In 57 cases of MCL (81.4%) cytological analysis revealed a classical cytology and in 13 cases (18.6%) a blastoid cytological subtype. Immunophenotyping showed coexpression of CD20 and CD5 in all cases and negativity of the tumour cells for CD23. Cyclin D1 staining was positive in 69 cases (98.6%). In one case (1.4%) cyclin D1 staining could not be evaluated for technical reasons.

Minichromosome maintenance protein 6 staining was restricted to the cell nucleus. The expression level ranged from 12.0 to 95.6%, with a median of 64.6% and a mean of 61.0% (Figures 1A and B). We retrieved data on Ki-67 expression from our previous investigation on the same collection of samples (Schrader et al, 2004). As expected, the MCM6 index was significantly higher than the Ki-67 index (Figure 2, $P < 0.0001$), with a mean for Ki-67 of 19.8%, compared to 61.0% for MCM6. Also not unexpectedly, the two markers showed a significant correlation (Figure 3, $P < 0.0001$). Surprisingly, cytological variants like the blastoid variant did not differ in their MCM6 expression level ($P = 0.2672$).

In contrast, in our previous and other studies (Lardelli et al, 1990; Ott et al, 1997; Campo et al, 1999), the Ki-67 index was significantly higher in blastoid variants than in cases with classical cytology. By calculating the ratio of MCM6 and Ki-67, the majority of cases had high indices (mean: $4.7 \pm 4.6$).

Univariate analysis of MCM6 expression in relation to clinical characteristics revealed no significant differences concerning age, sex, stage of the disease, bone marrow infiltration, extranodal involvement, lactate dehydrogenase level and IPI score (Table 1). The only significant differences concerned B-symptoms and WHO status (Table 1). A multivariate analysis of 52 patients with complete data for all variables showed that only MCM6 expression ($P < 0.0001$) and IPI ($P = 0.0018$) were prognostic factors for the clinical outcome (Table 2) in our group of patients.

The patients were ranked according to their MCM6 expression level and divided into four equal quartiles (Table 3). Figure 4 shows the Kaplan–Meier analysis of overall survival time for patients in different quartiles. These data indicate that the MCM expression can identify patients with a good and a poor prognosis. The median survival times for the quartiles are listed in Table 3. In accordance with Ramnath et al (2001), we analysed the MCM expression in four categories. Patients with an MCM6 expression level of lower than 25% had not yet reached a median survival, in contrast to 38.2 months for the group with 25–50%, 30 months for the group with 50–75% and 16.0 months for patients with more than 75% (Figure 5 and Table 3, $P < 0.0001$).

DISCUSSION

Minichromosome maintenance proteins are components of the prereplicative complex and are essential for the initiation of DNA replication (Labib et al, 2001). With the development of
monoclonal antibodies against MCM proteins, their use as proliferation markers for the analysis of archived tissue has become possible. To date, most studies have focused on MCM2 expression, for example, in oral squamous cell carcinomas (Kodani et al., 2003), prostate cancer (Meng et al., 2001; Padmanabhan et al., 2004) and ovarian serous neoplasms (Scott et al., 2004) chondrosarcoma (Helfenstein et al., 2004), oligodendrogial tumours (Wharton et al., 2001, 2004), oesophageal neoplasm (Going et al., 2002), renal cell carcinoma (Dudderidge et al., 2005), breast cancer (Gonzalez et al., 2004), endometrial carcinoma (Li et al., 2005) and thyroid carcinoma (Guida et al., 2005).

In a large study, Ramnath et al. (2001) examined 221 patients with lung cancer immunohistochemically for MCM2 expression and found MCM2 expression to be an independent prognostic factor for survival. In this study, patients with MCM2 expression in less than 25% of the tumour cells had a significantly better prognosis than patients with tumours with a higher MCM2 index. Additional to the study by Ramnath, only few studies have investigated MCM proteins immunohistochemically. Brake et al. (2003) focused on MCM7 in cervical cancer and Helfenstein et al. (2004) on MCM6 in chondrosarcoma using the monoconal antibody Ki-MCM6, also employed in our study.

The MCM expression in peripheral B-cell lymphomas was investigated for the first time by Obermann et al. (2001), who could demonstrate that also in MCLs the majority of lymphoma cells reside in the cell cycle phases G1, but not in S/G2/M. These data are in line with our results of repp86 in a large series of 94 patients with MCL (Schrader et al., 2005). Repp86 is a spindle apparatus-associated protein expressed only during S/G2/M, absent in G1 and G0, and thus displaying the same cell cycle expression pattern like geminin (Heidebrecht et al., 1997, 2003; Lygerou and Nurse, 2000; Wohlschlegel et al., 2000; Madine and Laskey, 2001; Hodgson et al., 2002). We could demonstrate that the majority of the 94 cases have lower repp86 expression than Ki-67, and this indicates a G1 arrest in the subset of cases in our collective.

Mantle cell lymphomas are mature B-cell neoplasms with a poor prognosis. Measures to predict the heterogeneous clinical outcome are in great need. To assess repp86 expression, we divided the 94 cases of our collective into four equal quartiles with regard to repp86 expression.

Table 3

| MCM6 expression | n (%) | Median OS (months) | 5-year survival (%) | P-value |
|-----------------|-------|--------------------|---------------------|---------|
| Quartile 1      | 18 (25.7) | 40.0              | 22.2               | <0.0001 |
| 12.0–44.7%      |       |                   |                    |         |
| Quartile 2      | 18 (25.7) | 36.0              | 11.1               |         |
| 49.0–65.6%      |       |                   |                    |         |
| Quartile 3      | 17 (24.3) | 25.4              | 0                  |         |
| 65.8–77.8%      |       |                   |                    |         |
| Quartile 4      | 17 (24.3) | 17.5              | 0                  |         |
| 79.2–95.6%      |       |                   |                    |         |
| 0–25%           | 5 (7.1)  | Not reached        | 60.0               | <0.0001 |
| >25–50%         | 14 (20.0)| 38.2              | 14.3               |         |
| >50–75%         | 32 (45.7)| 30.0              | 6.3                |         |
| >75–100%        | 19 (27.1)| 16.0              | 0                  |         |

OS = overall survival time.

Table 2

| Characteristics          | Reference level | Univariate (P-value) | Multivariate (P-value) |
|--------------------------|-----------------|----------------------|------------------------|
| MCM6 expression          | 0–25% vs >25–50% vs >50–75% vs >75% | <0.0001 | <0.0001 |
| Ki-67 expression         | <10% vs >10%    | 0.0045               | 0.2473                 |
| International prognostic index | 0–1 vs ≥2 | 0.0111               | 0.0018                 |
| LDH                      | Normal vs elevated | 0.0841               | 0.7638                 |
| Age                      | <60 vs >60      | 0.0083               | 0.5001                 |
| Sex                      | Male vs female  | 0.6679               | 0.8449                 |
| B-symptoms               | Yes vs no       | 0.0241               | 0.4884                 |
| Bone marrow infiltration | Yes vs no       | 0.0650               | 0.9970                 |
| Stage                    | 1–2 vs 3–4     | 0.6677               | 0.7943                 |
| Performance status (WHO) | 0–1 vs ≥2       | 0.0246               | 0.4430                 |

Figure 3 Correlation analysis of MCM6 and Ki-67 expression.
of the disease are needed to guide clinical decision-making. Studies of gene expression profiling in MCL have stressed the importance of cell proliferation for the clinical outcome. Rosenwald et al (2003) summarised predictive genes for survival as the ‘proliferation signature’ since most of these genes are thought to be involved in cell cycle progression, mitosis or DNA replication. Data from gene expression profiling experiments are describing transcriptional changes of mRNA and cannot necessarily be translated into protein expression. Furthermore, due to the high costs and technical obstacles like the need for fresh material, gene expression profiling is limited in its use for routine analysis of tumour samples. For these reasons, it is useful to confirm results based on gene expression profiling on the protein level with, for example, by immunohistochemistry. In a previous study, we studied topoisomerase IIexpression by immunohistochemistry and were able to confirm the results from Rosenwald et al (Schrader et al, 2004).

Since mRNA expression of MCM2, was reported to be associated with bad prognosis (Rosenwald et al, 2001), we evaluated MCM protein expression by immunohistochemistry in MCL. Out of the family of MCM proteins we chose MCM6 for our analysis, because it is highly reliable monoclonal antibody against this MCM family member was available (Heidebrecht et al, 2001).

First we ranked the patients according to their MCM6 expression level and divided into four equal groups (quartiles). Kaplan–Meier analysis showed significant differences in the overall survival time in different quartiles (Figure 4, Table 3, P < 0.0001). Second, for the Kaplan–Meier analysis, we chose different MCM6 expression levels according to the categories of Ramnath et al (2001). In the group under 25% MCM6-positive cells, the median overall survival time was despite the long follow-up time not reached, indicating that this group of patients has an excellent prognosis. The other patients with high MCM6 expression had a significantly shorter overall survival, with a median of 38.2 months in the group >25–50% positive cells compared to the group representing >50–75% MCM6-positive cells, which had a median of 30.0 months. The highly proliferating group of 75% and more MCM6-positive cells had a median survival time of only 16 months (P < 0.0001). In the multivariate Cox regression analysis which included Ki-67, only MCM6 expression (P < 0.0001) and IPI score (P = 0.0018) proved to be significant.

Figure 5 Kaplan–Meier analysis of overall survival time of patients with MCL and different MCM6 expression levels.

REFERENCES

Bertoni F, Zucca E, Cavalli F (2004) Mantle cell lymphoma. Curr Opin Hematol 11: 411 – 418

Brake T, Connor JP, Peteriet DG, Lambert PF (2003) Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res 63: 8173 – 8180

Brittinger G, Bartels H, Common H, Duhinke E, Fulle HH, Gunzer U, Gynes T, Heinz R, Konig E, Meusers P (1984) Clinical and prognostic
relevance of the Kiel classification of non-Hodgkin lymphomas. Results of a prospective multicenter study by the Kiel Lymphoma Study Group. **Hematol Oncol** 20: 269 – 306

Campo E, Raffeld M, Jaffe ES (1999) Mantle-cell lymphoma. **Semin Hematol** 36: 115 – 127

Chattrath P, Scott IS, Morris LS, Davies RJ, Rushbrook SM, Bird K, Vowler SL, Grant JW, Saeed IT, Howard D, Laskey RA, Coleman N (2003) Aberrant expression of minichromosome maintenance protein-2 and -6 in laryngeal squamous epithelial lesions. **Br J Cancer** 88: 1048 – 1054

Davidson EJ, Morris LS, Davies RJ, Rushbrook SM, Bird K, Laskey RA, Wilson GE, Kitchener HC, Coleman N, Stern PL (2003) Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasias. **Br J Cancer** 88: 257 – 262

Dudderidge TJ, Stoerker J, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH (2005) Mcm2, Geminin, and Ki67 define proliferative state and are prognostic markers in renal cell carcinoma. **Clin Cancer Res** 11: 2510 – 2517

Eh K, Björck E, Porwit-MacDonald A, Nordenskjold M, Borrebaeck CA (2004) Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. **Haematologia** 89: 686 – 695

Ewald KL, Obermann EC, Shreeram S, Loddo M, Fanshawe T, Williams C, Jung HI, Prevost AT, Blow J, Stoerker J, Williams GH (2004) DNA replication licensing in somatic and germ cells. **J Cell Sci** 117: 5875 – 5886

Freeman A, Morris LS, Mills AD, Stoerker J, Laskey RA, Williams GH, Coleman N (1999) Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. **Clin Cancer Res** 5: 2121 – 2132

Fujita M, Kiyono T, Hayashi Y, Ishibashi M (1997) p100: a novel proliferation-associated nuclear protein inhibitory of Cdt1/RLF-B following nuclear import. **Mol Biol Cell** 8: 32: 6568 – 6580

Heidebrecht HJ, Adam-Klages S, Szczepanowski M, Pollmann M, Buck F, Endl E, Kruse ML, Rudolph P, Parwaresch R (2003) repph6: a human protein associated in the progression of mitosis. **Mol Cell Res** 1: 271 – 279

Heidebrecht HJ, Buck F, Endl E, Kruse ML, Adam-Klages S, Andersen K, Fröhme SO, Schulte G, Wacker HH, Parwaresch R (2001) Ki-Mcm6, a new mammalian anaphase-promoting specific to Mcm6: comparison of the distribution profile of Mcm6 and the Ki-67 antigen. **Lab Invest** 81: 1163 – 1165

Heidebrecht HJ, Buck F, Steinmann J, Sprenger R, Wacker HH, Parwaresch R (1997) p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. **Blood** 90: 226 – 233

Heilmann A, Fröhme SO, Kramm M, Drescher W, Parwaresch R, Hassenplug J (2004) Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumours. Am J Clin Pathol 122: 912 – 918

Hodgson B, Li A, Tada S, Blow JY (2002) Geminin becomes activated as an inhibitor of Cdt1/RLF-B following nuclear import. **Mol Biol Cell** 12: 678 – 683

Hunter T, Pines J (1994) Cyclin and cancer. II: Cyclin D and CDK inhibitors come of age. **Cell** 79: 573 – 582

Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press

Kodani I, Osaki M, Shomori K, Araki K, Goto E, Byroek K, Ito H (2003) Minichromosome maintenance 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinomas. **J Oral Pathol Med** 32: 468 – 474

Labib K, Karsey SE, Diffley JP (2001) MCM2–7 proteins are essential components of prereplicative complexes that accumulate cooperatively in the nucleus during G1-phase and are required to establish, but not maintain, the S-phase checkpoint. **Mol Biol Cell** 12: 3658 – 3667

Lardielli P, Bookman MA, Sundeen J, Longo DL, Jaffe ES (1990) Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 14: 752 – 763

Li SS, Xue WC, Khoo US, Ngaan HY, Chan KY, Tam YJ, Chiu PM, Ip PP, Tam KF, Cheung AN (2005) Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. **Histopathology** 46: 307 – 313

Lindner K, Gregan J, Montgomery S, Kearsey SE (2002) Essential role of MCM proteins in premetiotic DNA replication. **Mol Biol Cell** 13: 435 – 444

Lyerou Z, Nurse P (2000) Cell cycle. License withheld – geminin blocks DNA replication. **Science** 290: 2271 – 2273

Madine M, Laskey R (2001) Geminin bans replication licenc. **Nat Cell Biol** 3: 1 – 6

Martinez N, Camacho Fl, Alpoga R, Rodriguez A, Ruiz-Ballesteros E, Martin P, Martinez-Climent JA, Garcia-Conde J, Menarguez J, Solano F, Mollejo M, Piris MA (2003) The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. **Cancer Res** 63: 8226 – 8232

Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoerker J, Mulley TW, Weinberg V, Carroll PR, Tlsty TD (2001) Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. **Clin Cancer Res** 7: 2712 – 2718

Meusers P, Engelhard M, Bartels H, Binder T, Fulle HH, Gorg K, Gunzer U, Havemann K, Kayser W, Konig E (1989) Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. **Hematol Oncol** 7: 365 – 380

Obermann EC, Ewald KL, Dogan A, Paul EA, Loddo M, Munson P, Williams GH, Stoerker K (2005) DNA replication licensing in peripheral B-cell lymphoma. **J Pathol** 206: 318 – 328

Ogawa Y, Takahashi T, Masukata H (1999) Association of fission yeast Orp1 and MCM6 proteins with chromosomal replication origins. **Mol Cell Biol** 19: 7228 – 7236

Ott G, Kalla J, Ott MM, Schreyen B, Katzenberger T, Muller JG, Muller-Hermelink HK (1997) Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. **Blood** 89: 1421 – 1429

Pachmannanban V, Callas P, Phillips G, Trainer TD, Beatty BG (2004) DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol: 57: 1057 – 1062

Ramnath N, Hernandez FJ, Tan DF, Huberman JA, Natarajan N, Beck AF, Hyland A, Todorov IT, Brooks JS, Bepler G (2001) Mcm2 is an independent predictor of survival in patients with non-small-cell lung cancer. **J Clin Oncol** 19: 4259 – 4266

Ratty R, Fransilka K, Jueno H, Teenerhovi L, Elonen E (2002) Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 69: 11 – 20

Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chadburn A, Giltnat M, Giltinan EM, Zhao H, Averett L, Hicklin DJ, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klaunser RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave DJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3: 185 – 197

Schradar C, Janssen D, Meusers P, Brittinger G, Siebmann JU, Parwaresch R, Tiemann M (2005) Repp86: a new prognostic marker in mantle cell lymphoma. Eur J Haematol, in press

Schradar C, Meusers P, Brittinger G, Meynaert A, Siebmann JU, Janssen D, Parwaresch R, Tiemann M (2004) Topoisomerase Ilpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. **Leukemia** 18: 1200 – 1206

Scott IS, Heath TM, Morris LS, Rushbrook SM, Bird K, Vowler SL, Arends MJ, Coleman N (2004) A new immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer 90: 1583 – 1590

Stoerker J, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bobrow L, Williams ED, Williams GH (2001) DNA replication licensing and human cell proliferation. J Cell Sci 114: 2027 – 2041

Tachibana KE, Gonzalez MA, Coleman N (2005) Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 205: 123 – 129
Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC, Croce CM (1984) Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. *Science* **224**: 1403 – 1406

Velders GA, Kluin-Nelemans JC, de BC, Hermans J, Noordijk EM, Schuuring E, Kramer MH, Van DW, Rahder JB, Kluin PM, van KJ (1996) Mantle-cell lymphoma: a population-based clinical study. *J Clin Oncol* **14**: 1269 – 1274

Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH (2001) Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. *Neuropathol Appl Neurobiol* **27**: 305 – 313

Wharton SB, Hibberd S, Eward KL, Crimmins D, Jellinek DA, Levy D, Stoeber K, Williams GH (2004) DNA replication licensing and cell cycle kinetics of oligodendrogial tumours. *Br J Cancer* **91**: 262 – 269

Wohlschlegel JA, Dwyer BT, Dhar SK, Cvetic C, Walter JC, Dutta A (2000) Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. *Science* **290**: 2309 – 2312